Y
Yeonhee Kim
Researcher at Bristol-Myers Squibb
Publications - 38
Citations - 1874
Yeonhee Kim is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Idelalisib & Rituximab. The author has an hindex of 14, co-authored 36 publications receiving 995 citations. Previous affiliations of Yeonhee Kim include Celgene.
Papers
More filters
Journal ArticleDOI
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Jeremy S. Abramson,M. Lia Palomba,Leo I. Gordon,Matthew A. Lunning,Michael Wang,Jon E. Arnason,Amitkumar Mehta,Enkhtsetseg Purev,David G. Maloney,Charalambos Andreadis,Alison R. Sehgal,Scott R. Solomon,Nilanjan Ghosh,Tina Albertson,Jacob Garcia,Ana Kostic,Mary Mallaney,Ken Ogasawara,Kathryn Newhall,Yeonhee Kim,Daniel Li,Tanya Siddiqi +21 more
TL;DR: Overall safety and activity of liso-cel did not differ by dose level, with a high objective response rate, and a low incidence of grade 3 or worse cytokine release syndrome and neurological events in patients with relapsed or refractory large B-cell lymphomas.
Journal ArticleDOI
A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia
Susan O'Brien,Nicole Lamanna,Thomas J. Kipps,Ian W. Flinn,Andrew D. Zelenetz,Jan A. Burger,Michael J. Keating,Siddhartha Mitra,Leanne Holes,Albert S. Yu,David W. Johnson,Langdon L. Miller,Yeonhee Kim,Roger Dansey,Ronald L. Dubowy,Steven Coutre +15 more
TL;DR: The combination of idelalisib and rituximab was highly active, resulting in durable disease control in treatment-naïve older patients with CLL, and support the further development of idELalisib as initial treatment of CLL.
Journal ArticleDOI
Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial
Andrew D. Zelenetz,Jacqueline C. Barrientos,Jennifer R. Brown,Bertrand Coiffier,Julio Delgado,Miklos Egyed,Paolo Ghia,Árpád Illés,Wojciech Jurczak,Paula Marlton,Marco Montillo,Franck Morschhauser,Alexander S. Pristupa,Tadeusz Robak,Jeff P. Sharman,David Simpson,Lukas Smolej,Eugen Tausch,Adeboye H. Adewoye,Lyndah Dreiling,Yeonhee Kim,Stephan Stilgenbauer,Peter Hillmen +22 more
TL;DR: Ielalisib plus BR is superior to BR alone, improving PFS and OS, and represents an important new treatment option for patients with R/R CLL.
Journal ArticleDOI
Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas
Jeremy S. Abramson,Maria Lia Palomba,Leo I. Gordon,Matthew A. Lunning,Michael L. Wang,Jon E. Arnason,Amitkumar Mehta,Enkhtsetseg Purev,David G. Maloney,Charalambos Andreadis,Alison R. Sehgal,Scott R. Solomon,Nilanjan Ghosh,Tina Albertson,Jacob Garcia,Ana Kostic,Daniel Li,Yeonhee Kim,Tanya Siddiqi +18 more
TL;DR: The seamless phase 1 TRANSCEND NHL 001 study evaluated liso-cel in pts with R/R large B cell NHL and presented data with long-term follow-up from pts treated in the DLBCL cohort, finding results were similar between DLs; therefore, data were pooled.
Journal ArticleDOI
Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study
Gilles Salles,Stephen J. Schuster,Sven de Vos,Nina D. Wagner-Johnston,Andreas Viardot,Kristie A. Blum,Christopher R. Flowers,Wojciech Jurczak,Ian W. Flinn,Brad S. Kahl,Peter Martin,Yeonhee Kim,Sanatan Shreay,Matthias Will,Bess Sorensen,Madlaina Breuleux,Pier Luigi Zinzani,Ajay K. Gopal +17 more
TL;DR: Patients with follicular lymphoma are diagnosed with a disease considered treatable, but not curable, with currently available therapeutic options, and survival in patients with FL has improved with the passage of time.